[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 352
56. Wang TB, Deng MH, Qiu WS, Dong WG: Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol; 2007 Mar 28;13(12):1794-7; discussion 1797-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer.
  • AIM: To investigate whether serum vascular endothelial growth factor-C (SVEGF-C), VEGF-C, and lymphatic vessel density (LVD) in tumor tissues are related to lymph node metastasis (LNM) and prognosis in gastric cancer.
  • METHODS: SVEGF-C levels of 80 gastric cancer patients and 20 healthy donors were examined using ELISA.
  • RESULTS: The SVEGF-C level in gastric cancer patients (595.9 +/- 201.0 ng/L) was significantly higher (P = 0.000) than controls (360.0 +/- 97.4 ng/L).
  • VEGF-C expression up-regulation was significantly related to differentiation, depth of invasion, LNM, distant metastasis, and pTNM stage (P = 0.000).
  • CONCLUSION: SVEGF-C level, VEGF-C and LVD are related to LNM and poor prognosis of patients with gastric cancer.
  • SVEGF-C may be a biomarker for LNM in gastric cancer.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / secondary. Lymphatic Vessels / pathology. Stomach Neoplasms / blood. Stomach Neoplasms / pathology. Vascular Endothelial Growth Factor C / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465468.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC4149954
  •  go-up   go-down


57. Chou NH, Chen HC, Chou NS, Hsu PI, Tseng HH: Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J Gastroenterol; 2006 Nov 28;12(44):7188-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma.
  • AIM: To investigate the clinical and pathological significance of altered retinoblastoma (Rb) encoding protein (pRb) in gastric carcinoma.
  • METHODS: Expression of altered pRb was analyzed in 91 patients with gastric adenocarcinoma by immunohistochemistry.
  • RESULTS: Sixty-five percent (59/91) of the tumors were positively stained and the staining in tumor nuclei of gastric carcinoma ranged 0%-90%.
  • Moreover, strong expression of altered pRb was found in 35% (6/17), 24% (5/21), 17% (8/46) and 0% (0/7) of T1, T2, T3 and T4 gastric carcinomas, respectively.
  • In terms of prognostic significance, univariate analysis showed that poor differentiation [41 (66.1%) vs 34 (42.5%) P = 0.051], advanced tumor stage (P < 0.001) and weakly altered pRb expression [17 (80.5%) vs 58 (49.6%) P=0.044] were associated with worse prognosis in these patients.
  • However, multivariate analysis revealed that advanced tumor stage was the only independent poor prognostic factor (P < 0.001).
  • CONCLUSION: the mutation of Rb gene is frequent in gastric carcinoma.
  • The expression of altered pRb inversely correlates with tumor invasion and is not an independent prognostic marker in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Retinoblastoma Protein / metabolism. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7762-6 [2217208.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):988-93 [2180983.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1138-46 [1659741.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2305-9 [1766677.001]
  • [Cites] Oncogene. 1992 Jan;7(1):101-8 [1741157.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 19;84(16):1251-6 [1640484.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):781-4 [8449603.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):695-9 [8158700.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):161-7 [8026875.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1018-24 [7947078.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1252-7 [7526887.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):442-5 [8621224.001]
  • [Cites] Br J Cancer. 1997;75(1):87-93 [9000603.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3301-12 [9363859.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):604-8 [10567906.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):618-22 [10567909.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):643-6 [2877398.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1394-9 [3823889.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Oncogene. 1989 Jun;4(6):725-9 [2543943.001]
  • [Cites] Oncogene. 1989 Jul;4(7):839-43 [2755701.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1343-6 [1886710.001]
  • (PMID = 17131485.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Other-IDs] NLM/ PMC4087784
  •  go-up   go-down


58. Stephens MR, Blackshaw GR, Lewis WG, Edwards P, Barry JD, Hopper NA, Allison MC: Influence of socio-economic deprivation on outcomes for patients diagnosed with gastric cancer. Scand J Gastroenterol; 2005 Nov;40(11):1351-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of socio-economic deprivation on outcomes for patients diagnosed with gastric cancer.
  • OBJECTIVE: Socio-economic deprivation has an influence on the outcome for patients diagnosed with breast, colorectal and bronchial cancer, but there are few data on its association with gastric cancer.
  • The aim of this study was to determine the influence of socio-economic deprivation on outcomes for patients with gastric cancer.
  • MATERIAL AND METHODS: Three hundred and thirty consecutive patients with gastric adenocarcinoma presenting to a single hospital between 1 October 1995 and 30 June 2004 were studied prospectively and deprivation scores calculated using the National Assembly for Wales Indices of Multiple Deprivation.
  • There was no correlation between stage of disease and socio-economic deprivation.
  • These poorer outcomes were not explained by the stage of disease at diagnosis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Cause of Death. Patient Care / standards. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334445.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


59. Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun MH, Fu H: The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol; 2010 Dec;17(12):3354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
  • BACKGROUND: Fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism, located in the FGFR4 gene exon 9, was reported to be associated with malignant tumors prognosis; however, there has been no relevant research for gastric cancer.
  • The purpose of this study was to investigate the clinical significance of FGFR4 Gly388Arg polymorphism as well as the mRNA expression of FGFR4 in patients with gastric cancer.
  • METHODS: The mRNA expression of FGFR4 in 103 gastric cancer tissues and corresponding normal tissues were measured by reverse transcription polymerase chain reaction (PCR) and real-time quantitative PCR.
  • PCR-restriction fragment length polymorphism analysis was performed to detect the FGFR4 Gly388Arg in 103 gastric cancer tissues.
  • FGFR4 expressions in mRNA levels were higher in gastric cancer tissues compared with those in relevant normal tissues.
  • Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054-4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658-7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on this study, FGFR4 Arg388 genotype-a marker for gastric cancer progression-may predict prognosis of gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Carcinoma, Signet Ring Cell / genetics. Gastric Mucosa / pathology. Polymorphism, Genetic / genetics. Receptor, Fibroblast Growth Factor, Type 4 / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20844967.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4
  •  go-up   go-down


60. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, Noh SH: Advanced gastric carcinoma with signet ring cell histology. Oncology; 2007;72(1-2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced gastric carcinoma with signet ring cell histology.
  • BACKGROUND: Gastric signet ring cell carcinoma (SRC) is a histological type based on microscopic characteristics and not on biological behavior.
  • This study compared the clinicopathological features and prognosis of advanced SRC with non-signet ring cell adenocarcinoma (NSRC) of the stomach.
  • METHODS: We reviewed the records of 4,759 consecutive patients diagnosed with advanced gastric adenocarcinoma who were resected surgically from 1987 to 2003.
  • RESULTS: Significant differences were noted in tumor size, Borrmann type, depth of invasion, lymph node metastasis, peritoneal dissemination and TNM stage.
  • CONCLUSIONS: Advanced gastric SRC tends toward deeper tumor invasion and more lymph node and peritoneal metastasis than NSRC.
  • Advanced gastric SRC had a worse prognosis than NSRC.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology


61. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • P53 expression was detected in 42.9% (15 of 35) of gastric cancer tissues of the patients.
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Asoglu O, Karanlik H, Parlak M, Kecer M, Muslumanoglu M, Igci A, Ozmen V, Gulluoglu M, Kapran Y: Metastatic lymph node ratio is an independent prognostic factor in gastric cancer. Hepatogastroenterology; 2009 May-Jun;56(91-92):908-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio is an independent prognostic factor in gastric cancer.
  • BACKGROUND/AIMS: The metastatic status of the regional lymph node is the most significant prognostic factor for gastric cancer.
  • The aim of this study is to evaluate the prognostic significance of the ratio of metastatic to examined lymph nodes (N ratio) for identifying a high-risk subgroup of patients with gastric cancer.
  • METHODOLOGY: The postoperative survival of 264 consecutive patients with operable gastric cancer was analyzed with regard to its N ratio and current N classification.
  • Cox regression analysis revealed that N ratio was sensitive prognostic factor in these surgically treated patients, which were also significantly correlated with extent of lymph node dissection and pathologic tumor stage (p<0.05).
  • CONCLUSIONS: N ratio can be recommended as an applicable parameter for lymph node involvement of gastric cancer.
  • It is a more effective and precise indicator for prognostic stratification of patients with lymph node positive gastric cancer than the current N classification of the tumor-node-metastasis system.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621727.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


63. Dumot JA, Vargo JJ 2nd, Falk GW, Frey L, Lopez R, Rice TW: An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc; 2009 Oct;70(4):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASUREMENTS: Histologic response was defined by the worst pathology obtained at any level of the esophagus or gastric cardia in 1 of 3 categories:.
  • Twenty-seven of 30 patients (90%) had downgrading of pathology stage after treatment.
  • During follow-up, 3 of 6 patients with complete response had recurrence of dysplasia or cancer in the gastric cardia.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Carcinoma, Squamous Cell / therapy. Cryosurgery / methods. Esophageal Neoplasms / therapy


6
Advertisement
4. Huang Q, Huang Q, Lin W, Lin J, Lin X: Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis. J Cancer Res Clin Oncol; 2010 Aug;136(8):1275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis.
  • PURPOSE: This study aimed to investigate the expression level of human proteasome activator PA28beta subunit (PA28beta) in gastric adenocarcinomas (GA) tissues and investigate its potential role in GA carcinogenesis.
  • Decreased expression was dependent on histological type, TNM stage, and differentiation grade.
  • [MeSH-major] Adenocarcinoma / genetics. Muscle Proteins / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Mol Cancer Res. 2008 Mar;6(3):426-34 [18337449.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2480-9 [17363565.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1693-704 [15789341.001]
  • [Cites] Biochem J. 2000 Jan 1;345 Pt 1:1-15 [10600633.001]
  • [Cites] Curr Top Microbiol Immunol. 2002;268:73-89 [12083009.001]
  • [Cites] Trends Cell Biol. 2005 Jan;15(1):27-33 [15653075.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(13):1596-600 [15224184.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7803-10 [11691796.001]
  • [Cites] BMC Cancer. 2009 Nov 04;9:391 [19889225.001]
  • [Cites] Mol Cancer Ther. 2005 Aug;4(8):1157-66 [16093431.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Nov;134(11):1219-27 [18446369.001]
  • [Cites] Exp Mol Med. 2008 Dec 31;40(6):709-20 [19116456.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6221-30 [11012676.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):494-501 [18223224.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5936-42 [10557080.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):3959-62 [8033121.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2092-101 [16893879.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2546-57 [16331256.001]
  • [Cites] Ann Rheum Dis. 2006 Aug;65(8):1021-7 [16414974.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7815-22 [15944286.001]
  • [Cites] Arch Biochem Biophys. 2000 Dec 1;384(1):174-80 [11147828.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):98-103 [14661019.001]
  • [Cites] Discov Med. 2009 Jun;8(40):23-7 [19772838.001]
  • [Cites] Mol Cancer. 2006 Nov 24;5:64 [17123452.001]
  • [Cites] Mol Biol Rep. 1999 Apr;26(1-2):11-4 [10363640.001]
  • [Cites] EMBO J. 2001 Nov 1;20(21):5898-907 [11689430.001]
  • (PMID = 20140627.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Muscle Proteins; EC 3.4.25.1 / PSME2 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


65. Wang MS, Pan Y, Liu N, Guo C, Hong L, Fan D: Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract; 2005 Jan;59(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of DARPP-32 in colorectal adenocarcinoma.
  • It may play an important role in gastric tumorigenesis.
  • Our aim is to investigate the expression of DARPP-32 protein in colorectal adenocarcinoma.
  • The expression of DARPP-32 in colorectal adenocarcinoma tissues 33/42, 78.57% was higher than that in normal colon epithelial tissues (31/60, 51.67%, p <0.05).
  • There was no significant relationship between the expression of DARPP-32 and the differentiation, metastasis and Dukes' stage of colorectal adenocarcinoma (p >0.05).
  • Both DARPP-32 and its truncated isoform t-DARPP were overexpressed in colorectal adenocarcinoma (t=2.306, p=0.028), while t-DARPP was more frequently detected.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Nerve Tissue Proteins / metabolism. Phosphoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707466.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine and cAMP-Regulated Phosphoprotein 32; 0 / Nerve Tissue Proteins; 0 / Phosphoproteins
  •  go-up   go-down


66. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • Methylation frequencies of stage III and IV tumor tissues was significantly higher than that in stage I and II tumor tissues (P = 0.01).
  • Positive immunostaining of stage III and IV tumor tissues was significantly lower than stage I and II tumor tissues (P<0.01).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


67. Smith BR, Stabile BE: Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy. J Gastrointest Surg; 2007 Feb;11(2):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma: reduction of perioperative mortality by avoidance of nontherapeutic laparotomy.
  • National trends indicate a longstanding decline in gastric adenocarcinoma due presumably to a decreasing prevalence of Helicobacter pylori infection.
  • Nonetheless, surgical outcomes continue to include relatively high morbidity and mortality rates owing to the advanced stage of disease encountered.
  • We hypothesize that recent immigration patterns are responsible for a leveling off or even reversal of the declining incidence of gastric cancer associated with H. pylori infection.
  • A retrospective review of a consecutive case series at a public teaching hospital located in an area of high immigration was conducted that included all patients presenting, from 1995 through 2004, with gastric adenocarcinoma.
  • There was no decline in the frequency of gastric adenocarcinoma among the study population over the 10 years.
  • The operation rate decreased and the gastric resection rate increased from the early period to the recent period as fewer incurable advanced stage (M1) patients underwent exploratory laparotomy and were palliated by nonoperative means.
  • We conclude that in an area of high immigration there has been no decline in gastric adenocarcinoma rates over the past decade, and the marked reduction in perioperative mortality was due to near elimination of nontherapeutic laparotomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Laparotomy / mortality. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6220-32 [16135489.001]
  • [Cites] Br J Surg. 1988 Jul;75(7):708-12 [2458160.001]
  • [Cites] Gut. 2005 Nov;54(11):1541-5 [15955787.001]
  • [Cites] Am Surg. 2005 Sep;71(9):797-801 [16468522.001]
  • [Cites] Br J Surg. 1996 Sep;83(9):1260-2 [8983624.001]
  • [Cites] Ann Surg. 1988 Jan;207(1):7-13 [3337564.001]
  • [Cites] Curr Probl Surg. 2005 Dec;42(12):796-862 [16344044.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S30-6 [7762737.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):347-51 [8658218.001]
  • [Cites] Curr Probl Surg. 2005 Nov;42(11):756-89 [16310017.001]
  • [Cites] Gastrointest Endosc. 1994 Nov-Dec;40(6):694-9 [7859967.001]
  • [Cites] Endoscopy. 1992 Jun;24(5):424-7 [1505491.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4509-17 [16002841.001]
  • [Cites] Surgery. 1993 Jan;113(1):14-27 [8417483.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Gastroenterology. 1998 Jun;114(6):1169-79 [9609753.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12 ):1153-8 [9373284.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):1016-9 [11443448.001]
  • [Cites] Epidemiol Rev. 1986;8:1-27 [3533579.001]
  • [Cites] Semin Oncol. 1996 Jun;23 (3):336-46 [8658217.001]
  • [Cites] Pediatrics. 2001 Feb;107(2):373-80 [11158472.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 17390160.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Mühlmann G, Untergasser G, Zitt M, Zitt M, Maier H, Mikuz G, Kronberger IE, Haffner MC, Gunsilius E, Ofner D: Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Arch; 2010 Jun;456(6):635-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer.
  • Here, we investigated the expression of Dkk-3 protein in gastric cancer and its potential value as a prognostic marker.
  • Dkk-3 expression was analyzed by immunohistochemistry in 136 tumor samples and was correlated with microvessel density (MVD), tumor stage, and grading as well as the clinical outcome of the patients.
  • In tumor cells, overexpression of Dkk-3 was found in 41 (30.1%) of all cases and was correlated significantly to pT-stage (p < 0.05) and UICC stage (p < 0.05).
  • Dkk-3 expression in tumor vessels of patients with gastric cancer identifies a population of patients with relatively favorable prognosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Intercellular Signaling Peptides and Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):5027-36 [16568085.001]
  • [Cites] Int J Oncol. 2001 Jul;19(1):117-21 [11408931.001]
  • [Cites] Int J Cancer. 2008 Apr 1;122(7):1539-47 [18033687.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] J Surg Oncol. 1997 Aug;65(4):232-6 [9274786.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Oncogene. 2006 Oct 19;25(49):6528-37 [16751809.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):9-28 [12832961.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2234-6 [12805321.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Gene. 2002 Jan 9;282(1-2):151-8 [11814687.001]
  • [Cites] J Urol. 2004 Mar;171(3):1314-8 [14767340.001]
  • [Cites] Gene. 1999 Oct 1;238(2):301-13 [10570958.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 5;268(1):20-4 [10652205.001]
  • [Cites] Cancer Sci. 2009 Aug;100(8):1414-20 [19493271.001]
  • [Cites] Dis Markers. 2008;24(2):101-9 [18219095.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):707-13 [15226763.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):49-60 [19051296.001]
  • [Cites] Gene. 2003 Jan 2;302(1-2):179-83 [12527209.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3442-55 [19633687.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):1981-2 [11130529.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • (PMID = 20473620.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK3 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


69. David S, Kan T, Cheng Y, Agarwal R, Jin Z, Mori Y: Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer. Biochem Biophys Res Commun; 2009 Jan 16;378(3):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer.
  • Tachykinin-1 (TAC1) is the precursor protein for neuroendocrine peptides, including substance P, and is centrally involved in gastric secretion, motility, mucosal immunity, and cell proliferation.
  • Here we report aberrant silencing of TAC1 in gastric cancer (GC) by promoter hypermethylation.
  • TAC1 methylation and mRNA expression in 47 primary GCs and 41 noncancerous gastric mucosae (NLs) were analyzed by utilizing real-time quantitative PCR-based assays.
  • There was no significant association between TAC1 methylation and age, gender, stage, histological differentiation, or the presence of Helicobacter pylori.
  • Further studies are indicated to elucidate the functional involvement of TAC1 in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing. Protein Precursors / genetics. Stomach Neoplasms / genetics. Tachykinins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046942.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Precursors; 0 / Tachykinins; 0 / protachykinin
  •  go-up   go-down


70. Fang WL, Wu CW, Lo SS, Chen JH, Hsieh MC, Shen KH, Li AF, Tai LC, Lui WY: Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):1227-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma.
  • BACKGROUND/AIMS: Signet ring cell carcinoma and mucinous carcinoma are mucin-producing gastric cancers.
  • METHODOLOGY: From December 1987 to July 2005, a total of 1612 gastric cancer patients received curative surgery, 128 patients with signet ring cell carcinoma and 48 with mucinous carcinoma were enrolled in this study.
  • RESULTS: Early stage (stage I and II) patients with mucinous carcinoma were associated with more male predominant (p = 0.002), larger tumor size (p = 0.020), deeper cancer invasion (p < 0.001), and a worse 5-year overall survival (63.6% vs 88.2%, p = 0.012) than those with signet ring cell carcinoma.
  • There was no significant difference between the two groups with advanced stage in 5-year overall survival.
  • CONCLUSIONS: Patients with mucinous carcinoma had different biological behaviors with those with signet ring cell carcinoma, in particular early stage, hence had a worse survival.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760976.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


71. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • Methylation frequencies of stage III and IV tumor tissues were significantly higher than that in stage I and II tumor tissues (p <.05).
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


72. Gasparini G, Inelmen EM, Enzi G, Santoro C, Sergi G, Cardin F, Terranova O: Clinical and prognostic aspects of gastric carcinoma in the elderly. J Gastrointest Surg; 2006 Mar;10(3):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and prognostic aspects of gastric carcinoma in the elderly.
  • The aim of the present study was to analyze the influence of various factors on the prognosis for elderly patients with gastric carcinoma.
  • They all had a histologically confirmed diagnosis of gastric adenocarcinoma.
  • On univariate analysis, significant prognostic factors in the two age groups were gender, stage, histotype (Lauren's intestinal type), Charlson index, and type of surgery (curative resection, palliative resection, and no surgery).
  • On multivariate analysis, independent prognostic factors were the Charlson index, tumor stage, and age group.
  • The 17-month survival rate was 55.6% for surgically treated patients and 0% for the untreated cases in stage 4 (P = 0.03).
  • Gastric cancer should be treated with conventional surgery even in the very elderly, since the survival rate for this age group does not differ significantly from the figures for younger patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1031-8 [8683633.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):520-5 [10947021.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1 Suppl 1):S51-2 [11989924.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):254-7 [10779055.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1582-7 [9552069.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S31-4 [12914387.001]
  • [Cites] World J Surg. 2000 Apr;24(4):465-72 [10706921.001]
  • [Cites] Oncology (Williston Park). 2002 Feb;16(2):183-9; discussion 194-6, 199 [11866135.001]
  • [Cites] Suppl Tumori. 2003 Sep-Oct;2(5):S35-8 [12914388.001]
  • [Cites] World J Surg. 1984 Jun;8(3):315-20 [6464488.001]
  • [Cites] Age Ageing. 2003 Sep;32(5):484-6 [12957994.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):451-3 [11504514.001]
  • [Cites] J Am Geriatr Soc. 1997 Apr;45(4):482-8 [9100719.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):29-34 [12080223.001]
  • [Cites] Minerva Chir. 2004 Oct;59(5):479-87 [15494675.001]
  • [Cites] Gastric Cancer. 2004;7(3):154-9 [15449203.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 15;89(20):1489-97 [9337345.001]
  • [Cites] Am Surg. 1987 Mar;53(3):170-3 [3826909.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):235-8 [15615661.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81 [15588798.001]
  • (PMID = 16504885.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Caruso RA, Napoli P, Nania A, Parisi A, Fedele F, Zuccalà V: Mitochondrion-rich differentiated adenocarcinomas of the stomach: clinicopathological, immunohistochemical and electron microscopy study of nine cases. Virchows Arch; 2010 May;456(5):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic and prognostic data of nine patients with mitochondrion-rich carcinomas (MRC) were compared retrospectively to data of 101 patients with conventional gastric adenocarcinomas.
  • MRC was defined as a tumour composed predominantly, or entirely, of columnar adenocarcinoma cells with eosinophilic cytoplasm and a strong supranuclear immunoreactivity for antimitochondrial antibody.
  • MRC showed immunohistochemical findings compatible with gastric differentiation (CK7+/CK20-/CDX-) When MRC were compared with non-MRC carcinomas, tumour size (< 4 cm vs >4 cm, P < 0.01) , frequency of lymph node metastases (11% vs. 80%, P < 0.01), low stage (I, II) at diagnosis (100% vs. 56%, P < 0.01), Goseki's group I (100% vs. 6%, P < 0.01), and better survival (0% vs. 70%, P < 0.01) differed significantly.
  • [MeSH-major] Adenocarcinoma / pathology. Mitochondria / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2009 Dec;55(6):665-82 [20002768.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1382-8 [17063077.001]
  • [Cites] Science. 1956 Aug 10;124(3215):269-70 [13351639.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] Int J Surg Pathol. 2008 Oct;16(4):447-9 [18387987.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Pathol Res Pract. 2007;203(7):539-41 [17590281.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98 [11483992.001]
  • [Cites] Hum Pathol. 2009 Apr;40(4):478-83 [19144383.001]
  • [Cites] Anat Rec. 1993 Jun;236(2):259-79 [8338232.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] Virchows Arch. 2009 May;454(5):481-95 [19343360.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Arch Pathol Lab Med. 2000 Oct;124(10 ):1547-52 [11035596.001]
  • [Cites] Histopathology. 2007 Nov;51(5):725-7 [17927604.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):116-23 [14720143.001]
  • [Cites] Front Biosci (Landmark Ed). 2010 Jan 01;15:595-603 [20036835.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] Gut. 1992 May;33(5):606-12 [1377153.001]
  • [Cites] Cell Death Differ. 2009 Jan;16(1):3-11 [18846107.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Hum Pathol. 2004 May;35(5):576-81 [15138932.001]
  • (PMID = 20393747.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


74. Ishii HH, Gobe GC, Ebihara Y: p53 is an indicator of tumor progression in early but not advanced gastric carcinomas. Hepatogastroenterology; 2007 Oct-Nov;54(79):2159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 is an indicator of tumor progression in early but not advanced gastric carcinomas.
  • BACKGROUND/AIMS: p53 plays an important role in the development of gastric carcinomas through its effect on apoptosis.
  • This project assessed its value in early and advanced stage gastric carcinomas.
  • METHODOLOGY: The characteristics of positive staining for p53 was evaluated in 202 gastric adenocarcinomas classified into early stage (T1) (127 cases) and advanced stage (T2, 3 and 4) (75 cases) using the tumor-node-metastasis classification.
  • RESULTS: The mucosa of early stage and both mucosa and subserosa of advanced cancers were examined. p53-positive early stage cancers had more apoptosis but also more proliferation than p53-negatives (P<0.05), perhaps indicating conferral of a growth advantage.
  • CONCLUSIONS: p53 may be useful as an indicator of development and progression in early stage gastric cancers but this is not the case for advanced stage gastric cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Apoptosis / physiology. Cell Proliferation. Disease Progression. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251181.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


75. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although the incidence of adenocarcinoma of the stomach has decreased over the past several decades, gastric cardia carcinoma has increased over the same period.
  • RESULTS: In the clinicopathologic analysis, patients who had cardia carcinoma tended to have tumors with poorly differentiated histology according to the World Health Organization classification system (P = 0.012), diffuse type according to the Lauren classification system (P = 0.049), and advanced pathologic TNM stage (P < 0.001).
  • In the multivariate analysis, tumor location in the cardia was confirmed as an independent, poor prognostic factor in patients with gastric carcinoma.
  • The current results support the hypothesis that cardia carcinoma forms a specific category of gastric carcinoma that is distinct from noncardia carcinoma.


76. Joo M, Kim H, Kim MK, Yu HJ, Kim JP: Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol; 2005 Jul;20(7):1039-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma.
  • However, the expression and distribution of Ep-CAM in gastric premalignant and malignant lesions are not well known.
  • METHOD: We examined the expression of Ep-CAM in 99 cases of gastric adenocarcinoma and associated uninvolved gastric mucosa, 39 cases of gastric biopsy specimens with chronic gastritis (CG) with or without intestinal metaplasia (IM) (25 cases) and gastric epithelial dysplasia (GED) (14 cases) by immunohistochemical staining.
  • In gastric adenocarcinoma, we correlated the results with established prognostic factors, and in IM and GED, with Hepatocyte paraffin 1 (Hep Par 1) expression, introduced as a marker of IM.
  • RESULTS: Ep-CAM overexpression was noted in 0% of normal epithelia, 93.9% of IM, 42.9% of GED and 34.3% of adenocarcinoma.
  • The average immunostaining score of normal epithelia, IM, GED and gastric adenocarcinoma was 0.14 (+/- 0.26), 7.18 (+/- 1.93), 5.67 (+/- 2.29) and 4.09 (+/- 1.89), respectively.
  • Ep-CAM overexpression in adenocarcinoma correlated with Lauren classification and histologic grade, but not with tumor stage, lymph node metastasis and p53 expression.
  • CONCLUSION: Our findings suggest that increased levels of Ep-CAM represent an early event in gastric carcinogenesis, and seem to have a specific relation with the development of IM as a morphoregulatory molecule.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Gastric Mucosa / metabolism. Intestines / pathology. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955212.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human
  •  go-up   go-down


77. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, Pop F, Radu H, Al-Hajaar N, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocan T: [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Mar-Apr;103(2):181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical aspects with prognostic value in gastric cancer--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Aspecte clinice cu implicaţie prognostică în cancerul gastric--analiză a 468 cazuri de adenocarcinom gastric.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which were operated in the 3rd Surgical Clinic--Cluj Napoca--01.01.1998-31.12.2003.
  • Patients in pTNM 0 stage were significantly younger than the rest of patients, with an average of 7.5 years.
  • The male/female ratio was 1.7:1, this ratio being significantly higher in cases with proximal gastric cancers.
  • There was not found any significant correlation between the interval : onset of symptoms and surgery, and pTNM stage.
  • This significant group of patients studied has maintained characteristics encountered in populations with higher incidence of gastric adenocarcinoma, men being more frequently affected, distal localization and intestinal histologic type being encountered more frequently.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457096.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


78. Lee DY, Park CS, Kim HS, Kim JY, Kim YC, Lee S: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications.
  • OBJECTIVES: To investigate the role of maspin and p53 expression in the progression of gastric cancer, and its value as a prognostic indicator.
  • MATERIALS AND METHODS: The expression of maspin and p53 in 152 cases of gastric cancer was detected by immunohistochemistry and compared with the clinicopathologic tumor parameters.
  • The relationship between maspin and p53 expression was also analyzed in the gastric cancers.
  • Two patterns of immunostaining for maspin were seen in the maspin-positive gastric cancer cases: cytoplasm-only staining (67.0%, 73 of 109 cases) and staining of both cytoplasm and nucleus (33.0%, 36 of 109 cases).
  • Maspin expression showed a negative association with histologic grade, depth of invasion, metastasis, and TNM stage (all P<0.05).
  • p53 expression showed an association with node metastasis, and TNM stage (both P<0.05).
  • In univariate log-rank analysis, loss of maspin expression, histologic grade, distant metastasis, and TNM stage were associated with patient survival.
  • However, in multivariate analysis TNM stage and regional node metastasis were the only independent prognostic factors.
  • Maspin expression is inversely correlated with mutant p53 expression in gastric cancer, which suggests that maspin expression is regulated by the p53 pathway.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091326.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


79. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Peschos D, Vezyraki P, Kalfakakou V, Metsios A, Charalampopoulos A, Macheras A, Agnantis N, Evangelou A: Serum and tissue selenium levels in gastric cancer patients and correlation with CEA. Anticancer Res; 2009 Aug;29(8):3465-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and tissue selenium levels in gastric cancer patients and correlation with CEA.
  • MATERIALS AND METHODS: In eighty patients who had been operated on for primary gastric cancer, serum Se and carcinoembryonic antigen (CEA) levels were measured preoperatively using a fluorometric and immunoradiometric assay (IRMA), respectively.
  • The serum CEA was 12+/-1.9 U ml(-1) in the gastric cancer patients and 2.1 U ml(-1) in the control group (p<0.001).
  • There was no correlation between serum/tissue Se concentration and disease stage/histological type or gender in the patient group.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Intestinal Neoplasms / metabolism. Selenium / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661375.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; H6241UJ22B / Selenium
  •  go-up   go-down


80. Anagnostopoulos GK, Stefanou D, Arkoumani E, Chalkley L, Karagiannis J, Paraskeva K, Mathou N, Dellaporta E, Tsianos E, Agnantis NJ: Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study. Acta Gastroenterol Belg; 2007 Jul-Sep;70(3):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study.
  • Our aim was to immunohistochemically study Bax protein expression in gastric carcinomas and correlate its expression with clinicopathological parameters and prognosis.
  • PATIENTS AND METHODS: Immunohistochemistry was performed, using a monoclonal antibody against bax, in paraffin-embedded tumor specimens from 47 cases of gastric cancer.
  • Univariate analysis showed that the variables with a significant negative impact on survival were: high TNM tumour stage, depth of penetration in the gastric wall, lymph node involvement, and Bax protein expression.
  • CONCLUSION: Negative Bax expression in gastric cancer is associated with de-differentiation, lymph node metastases, and poor clinical prognosis.
  • Bax protein expression might play an important role in the development and phenotypic differentiation of gastric carcinomas and tumor progression.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. bcl-2-Associated X Protein / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal. Carcinoma / pathology. Carcinoma / secondary. Cell Differentiation / genetics. Coloring Agents. Disease Progression. Female. Gastric Mucosa / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074738.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / BAX protein, human; 0 / Coloring Agents; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


81. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P=0.0402 and 51.5 vs 84.6%, P=0.0247, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


82. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, van den Brule AJ, Middeldorp JM, Meijer CJ, Bloemena E: Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol; 2006 Jan;30(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases.
  • Recently, we showed that Epstein-Barr virus (EBV)-positive gastric carcinoma (GC) forms a distinct clinicopathologic entity with a better prognosis due to lower incidence of lymph node metastases (LN+).
  • Twenty EBV-positive primary tumors (PT) (9 LN+) were matched with 28 EBV-negative GC (11 LN+) for T- and N-stage, gender, and age.
  • [MeSH-major] Adenocarcinoma / pathology. Epstein-Barr Virus Infections / virology. Lymphatic Metastasis / immunology. Stomach Neoplasms / pathology. T-Lymphocytes, Cytotoxic / immunology. Tumor Virus Infections / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330943.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • The prognosis is poor, since detection is usually at a late stage and metastatic spread occurs early.
  • In addition, 40 gastric cardia cancers were investigated to compare the pattern of imbalance at these loci.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In gastric cardia cancers, loss ranged from 12% to 27% (of informative cases), being most frequent at marker D7S3037.
  • The difference between oesophageal and gastric adenocarcinomas was highest for polymorphic marker D7S483 (p=0.05).
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


84. Qiu MZ, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, Aziz F, Wang DY, Xu RH: Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma. J Transl Med; 2010;8:107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma.
  • BACKGROUND: The existence of circulating tumor cells (CTCs) in peripheral blood as an indicator of tumor recurrence has not been clearly established, particularly for gastric cancer patients.
  • We conducted a retrospective analysis of the relationship between CTCs in peripheral blood at initial diagnosis and clinicopathologic findings in patients with gastric carcinoma.
  • METHODS: Blood samples were obtained from 123 gastric carcinoma patients at initial diagnosis. mRNA was extracted and amplified for carcinoembryonic antigen (CEA) mRNA detection using real-time RT-PCR.
  • CEA mRNA expression significantly correlated with T stage and postoperative recurrence status (P = 0.001).
  • CONCLUSIONS: CEA mRNA copy number in peripheral blood at initial diagnosis was significantly associated with disease recurrence in gastric adenocarcinoma patients.
  • Real-time RT-PCR detection of CEA mRNA levels at initial diagnosis appears to be a promising predictor for disease recurrence in gastric adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoembryonic Antigen / genetics. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jan;16(1):128-32 [9440733.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3106-10 [9242433.001]
  • [Cites] Surg Today. 1998;28(7):701-6 [9697262.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1368-72 [9823981.001]
  • [Cites] Surg Today. 2005;35(6):436-41 [15912289.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):248-56 [16320073.001]
  • [Cites] Trends Mol Med. 2006 Mar;12(3):130-9 [16488189.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5972-7 [17062668.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] J Surg Res. 2008 Aug;148(2):205-9 [17936797.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):153-9 [19050704.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1432-9 [10735890.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):918-24 [11011120.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):85-9 [11146784.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):189-94 [11176124.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1647-53 [11410502.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):17-20 [11438448.001]
  • [Cites] Lab Invest. 2001 Oct;81(10):1351-61 [11598148.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4080-5 [11751505.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):548-53 [11802221.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):195-203 [12065095.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2073-84 [12114406.001]
  • [Cites] Int J Mol Med. 2003 Feb;11(2):217-21 [12525881.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1091-4 [12671691.001]
  • [Cites] Trends Mol Med. 2003 May;9(5):189-95 [12763523.001]
  • [Cites] Diagn Mol Pathol. 2003 Jun;12(2):88-95 [12766613.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):219-27 [14639606.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):531-7 [14760074.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):448-56 [15170447.001]
  • [Cites] Clin Oncol. 1984 Dec;10(4):325-32 [6210169.001]
  • [Cites] Eur J Cancer. 1991;27(11):1461-5 [1720636.001]
  • [Cites] Lancet. 1992 Sep 19;340(8821):685-9 [1381801.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):725-9 [7512130.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):166-9 [9008229.001]
  • [Cites] Gut. 1996 Nov;39(5):717-21 [9014772.001]
  • [Cites] Gut. 1997 Apr;40(4):512-5 [9176080.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):64-8 [9660027.001]
  • (PMID = 21040522.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / DNA Primers; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2989934
  •  go-up   go-down


85. Park JM, Kim JH, Park SS, Kim SJ, Mok YJ, Kim CS: Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II. World J Surg; 2008 Jun;32(6):1037-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II.
  • BACKGROUND: According to the fifth edition of the UICC TNM classification, stage II gastric cancer has three subgroups: T1N2M0, T2N1M0, and T3N0M0.
  • This study was designed to investigate the prognosis of stage II gastric cancer according to the T and N category to verify the accuracy of TNM staging for stage II and to determine the prognostic factors for patients with stage II gastric cancer by subgroup.
  • METHODS: Clinicopathologic data from 326 patients with stage II gastric cancer were studied.
  • Univariate survival analysis showed that age, gender, histological type, and the extent of lymph node dissection were significant prognostic factors for stage II gastric cancer.
  • Thus, our data support the accuracy of the TNM staging classification for stage II gastric cancer.
  • However, before recommending limited lymph node dissection for T2N1 stage disease, development of a preoperative method for prediction of depth of invasion and lymph node status is needed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lymph Node Excision. Neoplasm Staging. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2008 Sep;32(9):2127-8 [18563483.001]
  • [Cites] World J Surg. 1999 May;23(5):492-7; discussion 497-8 [10085399.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):173-178 [11957092.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1674-80 [11527695.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):252-9 [11922742.001]
  • [Cites] Surgery. 2000 Feb;127(2):129-35 [10686976.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):25-37 [11192920.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):16-20 [16788938.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1303-9 [8869090.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):334-6 [2021850.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1763-5 [10760749.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):559-62 [16446988.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7508-11 [16437724.001]
  • [Cites] World J Surg. 1993 May-Jun;17(3):410-4; discussion 415 [8337889.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • (PMID = 18347851.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Ye ZB, Ma T, Li H, Jin XL, Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1747-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma.
  • AIM: To explore the effect of intratumoral expressions of interleukin-12 (IL-12) and interleukin-18 (IL-18) on clinical features, angiogenesis and prognosis of gastric carcinoma.
  • METHODS: The expressions of IL-12 and IL-18 from 50 samples of gastric cancer tissue were analyzed by immunohistochemistry, and microvessel density (MVD) was determined with microscopic imaging analysis system.
  • IL-12 was significantly associated with pathologic differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage, and IL-18 was closely related to distant metastasis.
  • The multivariate analysis with Cox proportional hazard model revealed IL-12, MVD and T stage were independent prognostic factors.
  • CONCLUSION: The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Signet Ring Cell / metabolism. Interleukin-12 / metabolism. Interleukin-18 / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1999 Dec;13(15):2195-202 [10593867.001]
  • [Cites] Int J Urol. 2004 Aug;11(8):647-52 [15285756.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):126-9 [11471895.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Aug;26(4):302-6 [11559342.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2050-5 [11596019.001]
  • [Cites] Auris Nasus Larynx. 2004 Sep;31(3):239-45 [15364358.001]
  • [Cites] In Vivo. 1993 May-Jun;7(3):265-9 [8357968.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):38-43 [8847724.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):817-24 [9120387.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5070-7 [10227975.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43 [16060834.001]
  • [Cites] Cytokine. 2002 Aug 7;19(3):126-37 [12242079.001]
  • [Cites] FASEB J. 2003 Apr;17(6):728-30 [12594171.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):91-5 [14630085.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 [10639148.001]
  • (PMID = 17461482.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4146958
  •  go-up   go-down


87. Mizoshita T, Tsukamoto T, Tanaka H, Takenaka Y, Kato S, Cao X, Joh T, Tatematsu M: Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings. Pathol Int; 2005 Oct;55(10):611-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings.
  • The clinicopathological significance of colonic and small-intestinal phenotypes has hitherto remained unclear in gastric cancers.
  • The purpose of the present study was therefore to examine 86 gastric carcinomas histologically and phenotypically using several phenotypic markers, including colon-specific carbonic anhydrase 1 (CA1) and sucrase as small-intestine specific marker.
  • Of 86 gastric cancers, sucrase and CA1 expression was observed in 12 (14.0%) and only in two cases (2.3%), respectively, associated with other intestinal markers such as villin and mucin core protein (MUC)2.
  • In the sucrase cases, expression appeared independent of the stage.
  • No association was observed between colonic and small-intestinal phenotypes, and lymph node metastasis and postoperative survival in the advanced gastric cancer cases with intestinal phenotypic expression.
  • In conclusion, the data suggest that colonic phenotype occurs rarely in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colon / metabolism. Intestine, Small / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185290.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; EC 3.2.1.48 / Sucrase; EC 4.2.1.- / Carbonic Anhydrase I
  •  go-up   go-down


88. Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U: Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol; 2007 Mar;16(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
  • To explore the relevance of XIAP, Smac/DIABLO, and XAF1 for carcinogenesis and tumor progression, we analyzed 46 primary gastric adenocarcinomas and non-neoplastic gastric mucosa samples by quantitative real-time polymerase chain reaction.
  • XIAP, Smac/DIABLO, and XAF1 expression was found in all non-neoplastic gastric mucosa samples and all adenocarcinomas.
  • XIAP expression levels did not change between non-neoplastic gastric mucosa and adenocarcinomas or between carcinomas of early and advanced stages.
  • Importantly, the ratio of XIAP to XAF1 expression significantly (P=0.03) increased from non-neoplastic mucosa to adenocarcinomas and the increase was even higher in carcinomas of advanced stage (P=0.01).
  • In conclusion, an increased expression ratio of XIAP to XAF1 in combination with a disturbed expression of the XAF1 splice variants could be shown in gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis. Apoptosis Regulatory Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Alternative Splicing. Gastric Mucosa / metabolism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / genetics. Mitochondrial Proteins / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism. Up-Regulation. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471152.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XAF1 protein, human; 0 / XIAP protein, human
  •  go-up   go-down


89. Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol; 2010 Jan;17(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
  • BACKGROUND: The present study investigated the clinical significance of S100 calcium binding protein A4 in the development, progression, and metastasis of gastric cancer.
  • METHODS: Tumor tissue, adjacent normal tissue, and lymph node and peritoneal metastases were obtained from patients with gastric cancer, and their gene expression profiles were analyzed by Affymetrix GeneChip HG-U133A2.0 array.
  • The expression of S100A4 was detected by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) in gastric tumor tissue and lymph node and peritoneum metastasis.
  • Immunohistochemistry was employed to analyze S100A4 expression in 436 clinicopathologically characterized gastric cancer cases and in corresponding distant metastases from 61 patients.
  • The expression of S100A4 in lymph node and peritoneal metastases was significantly higher than that in gastric tumor tissue.
  • The expression of S100A4 messenger RNA (mRNA) or protein differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph node and peritoneal metastases.
  • Further multivariate analysis suggested that depth of invasion, lymph node and distant metastases, tumor-node-metastasis (TNM) stage, and upregulation of S100A4 were independent prognostic indicators for the disease.
  • Expression of S100A4 in gastric cancer is associated significantly with lymph node and distant metastases, and poor prognosis.
  • S100A4 may be a useful marker to predict development, progression, and metastasis of gastric cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastric Mucosa / metabolism. S100 Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Gastrectomy. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820999.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


90. Choi JH, Kim YB, Lim HY, Park JS, Kim HC, Cho YK, Han SW, Kim MW, Joo HJ: 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology; 2007 Jan-Feb;54(73):290-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
  • BACKGROUND/AIMS: Although adjuvant chemotherapy has demonstrated small but significant survival benefit in locally advanced gastric cancer in several meta-analyses, optimal chemotherapy regimen remains to be determined.
  • METHODOLOGY: We retrospectively analyzed the survival of 207 gastric cancer patients (stage IB: 19, II: 65, IIIA: 58, IIIB: 28, IV: 37) who underwent 5-fluorouracil (5-FU), mitomycin-C (MMC), and polysaccharide-K (PSK) chemoimmunotherapy (CITX) after curative resection (FM group).
  • The survival of FM group was compared with that of historical control cohort of 103 patients with almost identical stage distribution who received 5-FU and doxorubicin-based chemotherapy (FA group).
  • FM group showed superior 5-year OS (84.4% vs. 67.6%, p = 0.019) compared with FA group in stage IB or II patients without significant difference (p = 0.222) in stage IIIA to IV.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Mitomycin / administration & dosage. Peripheral Nerves / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419278.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


91. Mylonas I, Mayr D, Walzel H, Shabani N, Dian D, Kuhn C, Kunze S, Jeschke U, Friese K: Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis. Anticancer Res; 2007 Jul-Aug;27(4A):1975-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin 1, Thomsen-Friedenreich expression and galectin-1 binding in endometrioid adenocarcinoma: an immunohistochemical analysis.
  • BACKGROUND AND AIM: Altered mucin 1 (MUC1) secretion patterns have been implicated in several cancerous conditions including gastric, colorectal and breast carcinomas.
  • Additionally, MUC1 and TF were down-regulated in stage III/IV tumors, while a higher binding of gal-1 was observed in stage III/IV tumors, suggesting a substantial role of this antigen in endometrial carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649808.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Galectin 1; 0 / Mucin-1; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


92. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata S, Yamamoto H, Kim BS, Matsuki N, Sawa T, Noh SH, East Asia Surgical Oncology Group: Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology; 2007 Mar;54(74):634-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy.
  • BACKGROUND/AIMS: Lymph node dissection is an essential component of curative resection for advanced gastric cancer.
  • METHODOLOGY: Patients enrolled in the study had potentially curable gastric adenocarcinoma in an advanced stage, T2, T3 or T4/N1 or N2.
  • The stage migration by D4 was found in 10 (7.5%).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523339.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Greece
  •  go-up   go-down


93. Lee SY, Hwang I, Park YS, Gardner J, Ro JY: Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol; 2010 Jun;36(6):1461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes?
  • Gastric carcinoma is the most common cancer and the second most common cause of cancer-related death in Korea.
  • Among the category I prognostic factors of gastric carcinoma, lymph node metastasis (nodal status) is considered to be the strongest prognostic factor.
  • In the present study, we aimed to evaluate which lymph node assessment method, metastatic lymph node number vs. ratio of metastasis, was better to predict survival in comparison with known prognostic factors in advanced gastric carcinoma in Korea.
  • Based on our study, we demonstrate that the MLR was a simple and reproducible prognostic factor that supplemented the limitation of the conventional N staging system, and provided more accurate prognostic stratification in advanced gastric cancer.
  • The MLR demonstrated further survival influence in pN2 stage.
  • Moreover, with the relationship to pT stage, MLR showed better survival information than that of ordinary AJCC pN stage.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428770.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


94. Wang SJ, Wu ML, Zhang LW, Guo XQ, Xu ZB, Er LM, Wang SP, Gao Y, Cong QW: [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia]. Zhonghua Zhong Liu Za Zhi; 2008 Nov;30(11):853-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia].
  • OBJECTIVE: To evaluate the long-term effect and clinical value of endoscopic mucosal resection (EMR) with transparent cap for dysplasia and early-stage cancer of the esophagus and gastric cardia.
  • METHODS: From September 1996 to June 2007, 154 lesions in the esophagus or gastric cardia of 147 patients were treated using EMR with transparent cap.
  • Among the lesions, there were 69 early-stage squamous-cell carcinomas in 64 patients and 47 squamous cell precancerous lesions of the esophagus in 45 patients, with an average lesion size of (14.8 +/- 6.1) mm (range, 3-40 mm), furthermore, there were 23 early-stage adenocarcinomas in 23 patients and 15 precancerous lesions in the gastric cardia in 15 patients, with an average lesion size of (8.2 +/- 4.3) mm (rang, 5-25 mm).
  • The 5-year survival rate was 96.2% for early-stage esophageal cancer, and 100% for early cancer of the gastric cardia.
  • CONCLUSION: Endoscopic mucosal resection is suitable to treat precancerous lesions or early-stage esophageal cancers without invasion into submucosa.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


95. Song KY, Jung CK, Park WS, Park CH: Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. Jpn J Clin Oncol; 2009 May;39(5):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma.
  • OBJECTIVE: This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in Stage III gastric adenocarcinoma.
  • METHODS: We performed immunohistochemical staining for survivin, p53 and Bax in formalin-fixed, paraffin-embedded blocks from 157 surgically resected Stage III gastric cancer tissues.
  • RESULTS: Of the 157 gastric cancer tissues, 63 (40.1%) cases showed positive expression for survivin protein.
  • Survivin and p53 were independent prognostic factors in Stage III gastric cancer.
  • CONCLUSIONS: Survivin protein is an important predictive and prognostic parameter of poor outcome in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / mortality. Microtubule-Associated Proteins / genetics. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336448.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


96. Dong Q, Liu YP, Qu XJ, Hou KZ, Li LL: [Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance]. Chin J Cancer; 2010 Jan;29(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-Cbl, Cbl-b, and epidermal growth factor receptor in gastric carcinoma and their clinical significance].
  • This study investigated the expression of c-Cbl, Cbl-b, and EGFR in gastric carcinoma and its clinical significance.
  • METHODS: The expressions of c-Cbl, Cbl-b, and EGFR were detected by immunohistochemistry using tissue microarrays consisting of 124 specimens of gastric carcinoma and 16 specimens of normal gastric mucosa.
  • The relationship between the expressions of c-Cbl, Cbl-b, and EGFR and clinicopathologic factors of gastric carcinoma were analyzed statistically.
  • RESULTS: The positive rates of c-Cbl, Cbl-b, and EGFR were higher in the gastric carcinoma group than in the normal group (71.0% vs. 18.0%, P<0.01; 82.3% vs. 25.0%, P<0.01; 56.5% vs. 12.5%, P<0.01, respectively).
  • Synchronous strong-positive expressions of c-Cbl, Cbl-b, and EGFR were observed in 27 specimens of gastric carcinoma, most of which were at advanced stage.
  • CONCLUSIONS: Overexpressions of c-Cbl, Cbl-b, and EGFR are closely related to the invasion and progression of gastric carcinoma. c-Cbl and Cbl-b may serve as novel molecular markers for gastric carcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038312.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.3.2.- / Proto-Oncogene Proteins c-cbl; EC 6.3.2.19 / CBLB protein, human
  •  go-up   go-down


97. Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY, Lee KH, Lee JH: CpG methylation of transcription factor 4 in gastric carcinoma. Ann Surg Oncol; 2010 Dec;17(12):3344-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG methylation of transcription factor 4 in gastric carcinoma.
  • BACKGROUND: Epigenetic silencing of tumor-related genes by CpG island methylation is an important mechanism for the development of many tumors, including gastric carcinoma.
  • Deregulation of transcription factor 4 (TCF4) by promoter methylation was recently shown to play a key role in gastric carcinogenesis.
  • METHODS: The extent of methylation in the TCF4 promoter was assessed using methylation-specific polymerase chain reaction (MSP) and pyrosequencing (PS) in 120 gastric carcinoma (GC) samples collected during gastrectomy, and in 40 normal gastric mucosa samples.
  • There was a significant difference in TCF4 methylation between GCs and normal gastric mucosa (67.5 vs. 40.0%, respectively, by MSP and 75.8 vs. 30.0%, respectively, by PS; p < 0.05).
  • There was significant correlation between TCF4 methylation status by PS and tumor size (p = 0.004), Lauren classification (p = 0.043), depth of invasion (p < 0.001), nodal metastasis (p = 0.021), and tumor-node-metastasis (TNM) stage (p = 0.045).
  • CONCLUSIONS: These results suggest that inactivation of TCF4 by promoter methylation may play a role in the early stage of gastric carcinoma progression.
  • [MeSH-major] Adenocarcinoma / genetics. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Signet Ring Cell / genetics. CpG Islands / genetics. DNA Methylation / genetics. Gastric Mucosa / pathology. Stomach Neoplasms / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585880.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / TCF4 protein, human; 0 / Transcription Factors
  •  go-up   go-down


98. Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I: Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol; 2006 Apr;8(4):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
  • OBJECTIVE: To calculate the Normal Tissue Complication Probabilities (NTCP) for the liver, right kidney, left kidney and spinal cord, as well as the global Uncomplicated Tumour Control Probability (UTCP) in gastric cancer patients who underwent a treatment with radiotherapy after radical surgery in our environment.
  • MATERIAL AND METHOD: In April 2000, a postoperative chemotherapy (QT-RT) protocol started in the province of Malaga for Gastric Adenocarcinomas with postsurgical stage II or higher (pT3-4 and/or pN+).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Kidney / radiation effects. Liver / radiation effects. Radiation Injuries / diagnosis. Radiotherapy, Adjuvant / adverse effects. Spinal Cord / radiation effects. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [2032884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):283-93 [11872272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30 [2722599.001]
  • [Cites] Radiat Res Suppl. 1985;8:S13-9 [3867079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):439-47 [10760441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):589-98 [10701738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):983-93 [10705021.001]
  • (PMID = 16648103.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. Michelet P, D'Journo XB, Roch A, Papazian L, Ragni J, Thomas P, Auffray JP: Perioperative risk factors for anastomotic leakage after esophagectomy: influence of thoracic epidural analgesia. Chest; 2005 Nov;128(5):3461-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most important predisposing factors for anastomotic leaks are ischemia of the gastric conduit and low blood oxygen content.
  • PATIENTS: Two hundred seven patients who underwent one-stage esophagectomy between 1998 and 2003.
  • [MeSH-major] Adenocarcinoma / surgery. Analgesia, Epidural. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304300.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


100. Yu QS, Liu Y, Hou Y, Zhang F, Yi W, Wang X, Shuai J: [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Aug;25(8):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of early intestinal dripping of jianpi tongli Chinese herbs on serum level IL-2, sIL-2R and IL-12 in patients with gastric cancer after operation].
  • OBJECTIVE: To explore the regulation and clinical significance of intestinal dripping of Jianpi Tongli (JPTL) Chinese herbs on levels of serum cytokines, such as interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and interleukin-12 (IL-12) in treating patients with gastric cancer (GC) at early post-operational stage.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16152828.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 187348-17-0 / Interleukin-12
  •  go-up   go-down






Advertisement